Marksans Pharma shares rose 2.51% to ₹267.75 by early afternoon trade on Wednesday, touching an intraday high of ₹272.70 against a previous close of ₹261.20. According to latest market data, the stock traded with a volume of 25.19 lakh shares and a traded value of ₹67.44 crore. The stock has delivered superior returns in 2026, rising nearly 49% on a year-to-date basis, reflecting strong market confidence in the company's European expansion strategy.
The company has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company headquartered in Flensburg. As reported by ETPharma, the acquisition will be completed for a total cash consideration of €892,384 (approximately ₹10 crore) and is expected to be finalized by 31 July 2026. The deal is not classified as a related-party transaction as ABCnow's shareholders have no existing relationship with Marksans or its promoter group. No regulatory approvals are required to complete the transaction, making it a straightforward acquisition process.
According to ETPharma, ABCnow GmbH is a foreign company registered in Germany and operates as a pharmaceutical wholesale and distribution company primarily engaged in marketing and distribution of over-the-counter (OTC) pharmaceutical products across the German healthcare market. The company was incorporated in 2023 and achieved revenue of €510,215.60 in 2024 and €227,233.69 in 2025 as of December 31, 2025. The acquisition will enable Marksans to leverage ABCnow's front-end sales and marketing infrastructure for marketing products manufactured in India, UK, and USA regions, providing direct front-end sales and distribution capabilities in Germany.
As reported by ETPharma, the European market represents the second largest revenue contributor at 34% for Marksans Pharma in FY26, making this acquisition strategically significant for the company's global expansion. The acquisition is expected to strengthen Marksans' forward-integration strategy through direct, owned market-access capabilities in the European Union. The company stated that "the acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union."
According to Upstox, during FY26, Marksans Pharma delivered its highest-ever revenue at ₹3,000 crore, along with EBITDA of ₹601 crore and profit after tax of ₹420 crore. The company maintained its net-cash position of ₹990 crore, extending its multi-year track record of strong financial performance. Marksans Pharma is listed on the NIFTY MICROCAP 250 index and carries a total market capitalisation of ₹12,124.40 crore. The stock trades at a price-to-earnings multiple of 28.18, reflecting strong investor confidence in the company's growth prospects. In the latest quarter, the company reported a 63.59% increase in consolidated net profit to ₹148.13 crore on a 20.84% rise in revenue to ₹856.11 crore in Q4 FY26 compared with Q4 FY25.
